Astrazeneca Pharma India Ltd vs Desh Rakshak Aushdhalaya Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8316 as of 12 May 14:45 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Desh Rakshak Aushdhalaya Ltd changed from 4.5 on March 2021 to 29.5 on March 2025 . This represents a CAGR of 45.65% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Desh Rakshak Aushdhalaya Ltd changed from ₹ 1.82 crore on March 2021 to ₹ 13.38 crore on March 2025 . This represents a CAGR of 49.03% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 1.4 crore as compare to the Sep '25 revenue of ₹ 0.95 crore. This represent the growth of 47.37% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 0.25 crore as compare to the Sep '25 ebitda of ₹ 0.26 crore. This represent the decline of -3.85% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Desh Rakshak Aushdhalaya Ltd changed from ₹ 0.09 crore to ₹ 0.09 crore over 7 quarters. This represents a CAGR of 0.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Desh Rakshak Aushdhalaya Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Desh Rakshak Aushdhalaya Ltd

The flagship company Desh Rakshak Aushdhalaya Limited of Bhagwant Group was originally started in 1901 as a Proprietorship Concern by Late Shri Bhagwant Rai Jain, a well renowned Vaidya Father of Late Dr. Paras Kumar Jain.
The Concern was converted into a Private Limited Company in Jul.'94. Desh Rakshakare the oldest manufacturer of Pure Ayurvedic and Herbal Products as discovered by the Ancient Seers & Sages.
The medicines are categorized into Proprietary & Classical Medicines.
They are currently manufacturing around 450 products (Proprietary & Classical mix) and all of these medicines are manufactured as per the prescribed norms and standards of the Indian Government.
The Company was earlier operating the traditional process of manufacturing ayurvedic medicines. Up to 1976, the company producing ethical products of ayurvedic medicines which were supplied to ayurvedic dispensaries.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Desh Rakshak Aushdhalaya Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,347 Cr while Market cap of Desh Rakshak Aushdhalaya Ltd is 14 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd?

As of May 12, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8538.85. On the other hand, Desh Rakshak Aushdhalaya Ltd stock price is INR ₹24.8.

How do dividend payouts of Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Desh Rakshak Aushdhalaya Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.